{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T21:21:47Z","timestamp":1758057707837,"version":"3.44.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.ejphar.2019.03.011","type":"journal-article","created":{"date-parts":[[2019,3,7]],"date-time":"2019-03-07T12:25:54Z","timestamp":1551961554000},"page":"11-17","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Modulation of urinary frequency via type 1 lysophosphatidic acid receptors: Effect of the novel antagonist ASP6432 in conscious rats"],"prefix":"10.1016","volume":"853","author":[{"given":"Kazuyuki","family":"Sakamoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukiko","family":"Noguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Ueshima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akiyoshi","family":"Ohtake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuichi","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsunori","family":"Imazumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Takeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriyuki","family":"Masuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2019.03.011_bib1","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/nau.10052","article-title":"The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society","volume":"21","author":"Abrams","year":"2002","journal-title":"Neurourol. Urodyn."},{"key":"10.1016\/j.ejphar.2019.03.011_bib2","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.eururo.2010.10.035","article-title":"Effects of nitric oxide on the primary bladder afferent activities of the rat with and without intravesical acrolein treatment","volume":"59","author":"Aizawa","year":"2011","journal-title":"Eur. Urol."},{"issue":"Suppl 3","key":"10.1016\/j.ejphar.2019.03.011_bib3","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/bcpt.12577","article-title":"Potential future pharmacological treatment of bladder dysfunction","volume":"119","author":"Andersson","year":"2016","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"10.1016\/j.ejphar.2019.03.011_bib4","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.eururo.2010.07.026","article-title":"Nitric oxide\/cyclic guanosine monophosphate signalling mediates an inhibitory action on sensory pathways of the micturition reflex in the rat","volume":"58","author":"Caremel","year":"2010","journal-title":"Eur. Urol."},{"key":"10.1016\/j.ejphar.2019.03.011_bib5","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1111\/bju.12555","article-title":"Total urgency and frequency score as a measure of urgency and frequency in overactive bladder and storage lower urinary tract symptoms","volume":"113","author":"Chapple","year":"2014","journal-title":"BJU Int."},{"key":"10.1016\/j.ejphar.2019.03.011_bib6","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/j.2040-4603.2015.tb00596.x","article-title":"Neural control of the lower urinary tract","volume":"5","author":"de Groat","year":"2015","journal-title":"Compr. Physiol."},{"key":"10.1016\/j.ejphar.2019.03.011_bib7","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.urology.2007.06.1110","article-title":"Transient receptor potential channel A1 involved in sensory transduction of rat urinary bladder through C-fiber pathway","volume":"70","author":"Du","year":"2007","journal-title":"Urology"},{"key":"10.1016\/j.ejphar.2019.03.011_bib8","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.brainres.2004.07.005","article-title":"Evidence for biological effects of exogenous LPA on rat primary afferent and spinal cord neurons","volume":"1022","author":"Elmes","year":"2004","journal-title":"Brain Res."},{"key":"10.1016\/j.ejphar.2019.03.011_bib9","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1177\/1756287217742837","article-title":"Best practice in the management of storage symptoms in male lower urinary tract symptoms: a review of the evidence base","volume":"10","author":"Gacci","year":"2018","journal-title":"Ther. Adv. Urol."},{"key":"10.1016\/j.ejphar.2019.03.011_bib10","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1177\/1756287214531639","article-title":"A review of the use of tadalafil in the treatment of benign prostatic hyperplasia in men with and without erectile dysfunction","volume":"6","author":"Hatzimouratidis","year":"2014","journal-title":"Ther. Adv. Urol."},{"key":"10.1016\/j.ejphar.2019.03.011_bib11","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1111\/iju.12799","article-title":"Possible effect of lysophosphatidic acid on cell proliferation and involvement of lysophosphatidic acid and lysophosphatidic acid receptors in mechanical stretch-induced mitogen-activated protein kinase","volume":"22","author":"Kawashima","year":"2015","journal-title":"Int. J. Urol."},{"key":"10.1016\/j.ejphar.2019.03.011_bib12","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1113\/JP273961","article-title":"Lysophosphatidic acid-induced itch is mediated by signalling of LPA5 receptor, phospholipase D and TRPA1\/TRPV1","volume":"595","author":"Kittaka","year":"2017","journal-title":"J. Physiol."},{"key":"10.1016\/j.ejphar.2019.03.011_bib13","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/S0022-5347(05)68237-7","article-title":"Characterization of cultured bladder smooth muscle cells: assessment of in vitro contractility","volume":"162","author":"Kropp","year":"1999","journal-title":"J. Urol."},{"key":"10.1016\/j.ejphar.2019.03.011_bib14","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/j.1464-410X.2007.06872.x","article-title":"Effects of anaesthesia on the nitrergic pathway during the micturition reflex in rats","volume":"100","author":"Masuda","year":"2007","journal-title":"BJU Int."},{"key":"10.1016\/j.ejphar.2019.03.011_bib15","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.neuropharm.2017.08.032","article-title":"Analgesic effects of novel lysophosphatidic acid receptor 5 antagonist AS2717638 in rodents","volume":"126","author":"Murai","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejphar.2019.03.011_bib16","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.autneu.2010.02.006","article-title":"Correlation between pharmacologically-induced changes in cystometric parameters and spinal c-Fos expression in rats","volume":"156","author":"Nagabukuro","year":"2010","journal-title":"Auton. Neurosci."},{"key":"10.1016\/j.ejphar.2019.03.011_bib17","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/nchembio.712","article-title":"Lysophosphatidic acid directly activates TRPV1 through a C-terminal binding site","volume":"8","author":"Nieto-Posadas","year":"2011","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejphar.2019.03.011_bib18","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/j.1476-5381.1992.tb14483.x","article-title":"Effects of inhibition of the L-arginine\/nitric oxide pathway in the rat lower urinary tract in vivo and in vitro","volume":"107","author":"Persson","year":"1992","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2019.03.011_bib19","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/S0169-328X(99)00333-2","article-title":"Vzg-1\/lysophosphatidic acid-receptor involved in peripheral pain transmission","volume":"75","author":"Renback","year":"2000","journal-title":"Mol. Brain Res."},{"key":"10.1016\/j.ejphar.2019.03.011_bib20","doi-asserted-by":"crossref","first-page":"e93230","DOI":"10.1371\/journal.pone.0093230","article-title":"A novel highly potent autotaxin\/ENPP2 inhibitor produces prolonged decreases in plasma lysophosphatidic acid formation in vivo and regulates urethral tension","volume":"9","author":"Saga","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ejphar.2019.03.011_bib21","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1124\/jpet.118.247908","article-title":"Effect of ASP6432, a novel type 1 lysophosphatidic acid receptor antagonist, on urethral function and prostate cell proliferation","volume":"366","author":"Sakamoto","year":"2018","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2019.03.011_bib22","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ejphar.2019.01.014","article-title":"ASP6432, a type 1 lysophosphatidic acid receptor antagonist, reduces urethral function during urine voiding and improves voiding dysfunction","volume":"847","author":"Sakamoto","year":"2019","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2019.03.011_bib23","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.eururo.2011.09.002","article-title":"Expression of fatty acid amide hydrolase (FAAH) in human, mouse, and rat urinary bladder and effects of FAAH inhibition on bladder function in awake rats","volume":"61","author":"Strittmatter","year":"2012","journal-title":"Eur. Urol."},{"key":"10.1016\/j.ejphar.2019.03.011_bib24","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1021\/acsmedchemlett.7b00383","article-title":"Discovery of a slow tight binding LPA1 antagonist (ONO-0300302) for the treatment of benign prostatic hyperplasia","volume":"8","author":"Terakado","year":"2017","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejphar.2019.03.011_bib25","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/j.2042-7158.1982.tb04776.x","article-title":"Contractile actions of lysophosphatidic acids with a chemically-defined fatty acyl group on longitudinal muscle from guinea-pig ileum","volume":"34","author":"Tokumura","year":"1982","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejphar.2019.03.011_bib26","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/1744-8069-10-71","article-title":"Lysophosphatidic acid and its receptors LPA1 and LPA3 mediate paclitaxel-induced neuropathic pain in mice","volume":"10","author":"Uchida","year":"2014","journal-title":"Mol. Pain"},{"key":"10.1016\/j.ejphar.2019.03.011_bib27","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.eururo.2013.07.034","article-title":"Combination therapy with solifenacin and tamsulosin oral controlled absorption system in a single tablet for lower urinary tract symptoms in men: efficacy and safety results from the randomised controlled NEPTUNE trial","volume":"64","author":"van Kerrebroeck","year":"2013","journal-title":"Eur. Urol."},{"key":"10.1016\/j.ejphar.2019.03.011_bib28","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/nau.10128","article-title":"Clinical diagnosis of bladder outlet obstruction in men with lower urinary tract symptoms: reliability of commonly measured parameters and the role of idiopathic detrusor overactivity","volume":"22","author":"Vesely","year":"2003","journal-title":"Neurourol. Urodyn."},{"key":"10.1016\/j.ejphar.2019.03.011_bib29","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1194\/jlr.R046458","article-title":"LPA receptor signaling: pharmacology, physiology, and pathophysiology","volume":"55","author":"Yung","year":"2014","journal-title":"J. Lipid Res."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299919301608?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299919301608?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T22:25:39Z","timestamp":1757975139000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299919301608"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":29,"alternative-id":["S0014299919301608"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2019.03.011","relation":{},"ISSN":["0014-2999"],"issn-type":[{"type":"print","value":"0014-2999"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Modulation of urinary frequency via type 1 lysophosphatidic acid receptors: Effect of the novel antagonist ASP6432 in conscious rats","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2019.03.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}